Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was CAD 254 million compared to CAD 211.91 million a year ago. Net income was CAD 7.49 million compared to net loss of CAD 14.7 million a year ago. Basic earnings per share from continuing operations was CAD 0.07 compared to basic loss per share from continuing operations of CAD 0.13 a year ago. Diluted earnings per share from continuing operations was CAD 0.07 compared to diluted loss per share from continuing operations of CAD 0.13 a year ago.